Evidence reviewed: 8 November 2026. Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system—the brain, spinal cord and optic nerves—that can affect vision, sensation, movement, balance and many other functions. Some people experience distinct neurological attacks; others develop gradually progressive disability. Early recognition matters because specialist diagnosis and appropriately selected disease-modifying therapies (DMTs) can reduce inflammatory disease activity. Yet common symptoms such as fatigue, tingling or dizziness alone do not diagnose MS [1,2].
What happens in MS?
The immune system contributes to inflammation involving myelin, oligodendrocytes and nerve fibers in the central nervous system. This can disrupt conduction of electrical signals, producing neurological symptoms that depend on the location of injury. Lesions may appear in characteristic parts of the brain, spinal cord or optic nerve. Over time, disability may reflect both inflammatory attacks and processes that are not always associated with an obvious relapse [1,2].
MS is not contagious, and it is not caused by a single dietary deficiency or stressor. Risk is influenced by a complex combination of factors, including genetic susceptibility, environmental exposures and prior infection with Epstein–Barr virus. Those associations do not provide a simple clinical test for diagnosing a particular person’s symptoms.
Common early symptoms of multiple sclerosis
1. Optic neuritis and visual changes
Optic neuritis may cause blurred or reduced vision in one eye, reduced color intensity and pain when moving the eye. Symptoms typically evolve over hours to days. Although optic neuritis can occur with MS, it also has other causes, including neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD). Sudden or new vision loss needs prompt medical or ophthalmic assessment; do not self-diagnose MS [1,2].
2. Numbness, altered sensation or tingling
Abnormal sensation can involve an arm, leg, trunk or part of the face. A sensory episode may persist for days or weeks and sometimes be associated with weakness or imbalance. Brief, intermittent tingling in a hand or foot is far more often caused by another condition, such as nerve compression, and should not be interpreted as MS without neurological assessment.
3. Limb weakness or walking difficulty
People may notice dragging a foot, reduced hand dexterity, stiffness, imbalance or fatigue when walking. Spinal cord involvement can cause symptoms affecting both legs, including bladder changes. Progressive loss of mobility may develop in some disease courses. Rapidly worsening weakness, new inability to walk, or new urinary retention with neurological symptoms demands urgent assessment to exclude other emergencies.
4. Double vision, vertigo or coordination problems
Brainstem and cerebellar lesions can contribute to double vision, abnormal eye movements, vertigo, tremor or poor coordination. However, migraine, vestibular disorders and stroke can produce overlapping symptoms. Sudden focal neurological deficits, facial droop or speech difficulty require immediate stroke evaluation, not delayed MS testing.
5. Fatigue, bladder changes and cognitive symptoms
Fatigue is common in established MS and may be worsened by sleep disturbance, depression, infection, medications or anemia. Urinary urgency, constipation, neuropathic pain, mood changes and cognitive slowing can occur. These symptoms matter clinically but are not specific enough to establish an MS diagnosis on their own [1].
What is an MS relapse?
A typical relapse is a new or clearly worsening neurological deficit lasting at least 24 hours, without another explanation such as fever or infection, and usually separated from a previous attack by at least 30 days. Symptoms are often consistent with inflammation at a specific CNS site. Temporary worsening of old symptoms during heat exposure, fever or infection is sometimes called a pseudo-relapse and does not necessarily mean a new inflammatory lesion. Clinicians must distinguish the two because management differs [1].
MS symptoms can fluctuate for reasons unrelated to new disease activity; a symptom diary may help document onset, duration and associated circumstances but should never replace specialist evaluation.
How is MS diagnosed? The updated 2024 McDonald criteria
Diagnosis is made by a neurologist using clinical history, neurological examination, MRI and selected laboratory tests while carefully excluding alternative diagnoses. The 2024 revised McDonald criteria, published in 2025 and incorporated into NICE guideline NG220 in June 2026, update how evidence from clinical features and advanced biomarkers may establish MS earlier and with greater specificity [1,2].
Important updates include:
- Five CNS regions: the optic nerve is now an additional location in which characteristic lesions can help demonstrate dissemination in space, alongside periventricular, cortical/juxtacortical, infratentorial and spinal-cord regions.
- Supportive MRI biomarkers: the central vein sign and paramagnetic rim lesions can improve diagnostic specificity in particular scenarios.
- CSF evidence: intrathecal kappa free light chains can be considered alongside oligoclonal bands when appropriate, based on validated techniques.
- Broader presentations: diagnostic pathways now address some progressive or atypical presentations and selected people with incidental imaging findings, but require careful specialist application.
The revised criteria are not permission to diagnose MS from one isolated MRI white-matter spot or a positive blood test. MRI lesions due to migraine, small-vessel vascular disease or other conditions can mimic demyelination. NICE emphasizes referral to an MS specialist and exclusion of more common diagnoses before applying the criteria [1,2].
What tests may be used?
| Test | Clinical purpose |
|---|---|
| MRI brain and spinal cord | Identifies characteristic lesions and helps assess disease activity and differential diagnoses. |
| MRI of optic nerves, OCT or visual testing | Can support assessment when optic nerve inflammation is suspected. |
| CSF oligoclonal bands or kappa free light chains | Provides evidence of intrathecal inflammation in selected circumstances. |
| Other blood tests | Exclude alternative causes, such as B12 deficiency and selected autoimmune or infectious conditions. |
| AQP4-IgG and MOG-IgG when indicated | Assist distinction from NMOSD or MOGAD, which can require different treatments. |
Not every individual needs every test. Specific tests depend on age, symptoms, imaging findings and diagnostic uncertainty. Blood biomarkers and advanced imaging cannot be interpreted without clinical context [1,2].
Types and patterns of MS
Relapsing MS involves attacks or episodes of new neurological dysfunction with periods of recovery or stability. Some people later develop steadily progressive disability, described as secondary progressive MS. Primary progressive MS involves gradual progression from onset, generally without obvious initial relapses. These categories guide monitoring and treatment eligibility but do not predict the exact future course for an individual [1].
How is an acute relapse treated?
For a relapse that significantly affects usual activities, NICE recommends considering high-dose methylprednisolone after appropriate assessment. The guideline recommends oral methylprednisolone 0.5 g daily for five days, and considers IV methylprednisolone 1 g daily for three to five days when oral treatment fails or is unsuitable, or if hospital treatment is required [1]. Steroids are typically used to speed recovery from an inflammatory attack; they do not replace long-term DMTs and are not indicated for every mild sensory symptom. Infection or another cause of deterioration should be assessed first.
High-dose steroids can cause insomnia, mood disturbance, increased blood glucose and other adverse effects; patients require an individualized plan. Do not initiate steroid courses without neurologist assessment.
Disease-modifying therapies: why early specialist care matters
DMTs aim to reduce inflammatory relapses and new MRI lesions and, for suitable patients, limit future disability accumulation. Treatment choice is individualized by disease activity, clinical pattern, age, comorbidities, pregnancy plans, infection risk, monitoring requirements and local access [1].
Available treatment classes include interferon-beta and glatiramer acetate; oral agents such as fumarates, teriflunomide, fingolimod-class modulators and cladribine; and monoclonal antibodies such as ocrelizumab, ofatumumab, natalizumab and ublituximab in eligible populations. These medicines are not interchangeable and may require infection screening, vaccines, blood monitoring, imaging and counseling about serious adverse effects. Some are used for highly active relapsing disease and others have indications in certain progressive forms. NICE’s June 2026 recommendations refer to individual technology appraisals rather than a universal preferred drug [1].
None of the currently used DMTs can guarantee a cure. Starting DMTs after an appropriately established diagnosis can be valuable, but the original article oversimplified management by implying that a course of steroids followed by any DMT is a standard sequence for all early symptoms. Decision-making requires specialist diagnosis and discussion of individualized benefit versus risk.
Rehabilitation and everyday care
MS care extends beyond immunomodulation. Physiotherapy, occupational therapy, exercise and strategies to manage fatigue, spasticity, bladder symptoms, pain, mood and cognition can improve function and quality of life. NICE encourages physical activity where possible, smoking cessation and vitamin D intake consistent with dietary guidance; high-dose vitamin D is not a proven alternative DMT [1].
Vaccination and infection prevention should be reviewed with the specialist because some DMTs affect immune responses. A person planning pregnancy should discuss treatment before conception rather than abruptly discontinuing medication.
Frequently asked questions
Can tingling alone diagnose MS?
No. Many conditions cause tingling. MS diagnosis requires clinical and paraclinical evidence interpreted by a specialist [1,2].
Can MRI confirm MS by itself?
Not always. Even lesions in characteristic locations must be interpreted with symptoms and alternatives; the 2024 criteria have precise pathways and safeguards [1,2].
What changed in the McDonald criteria?
The optic nerve became a fifth location, and select MRI and CSF biomarkers can now help establish MS in defined clinical situations [2].
Are high-dose steroids necessary for every relapse?
No. Clinically significant relapses may warrant treatment after assessing severity and excluding infection; mild relapses do not always need steroids [1].
Can exercise worsen MS permanently?
Activity can temporarily increase fatigue or symptoms when overheating occurs, but appropriate adapted exercise is generally beneficial. Individual tolerance and safety matter.
Key takeaways
Recognize characteristic neurological episodes, evaluate urgent warning signs and seek specialist assessment. Diagnosis follows the updated 2024 McDonald criteria as incorporated by NICE in 2026. DMTs require individualized specialist selection, while rehabilitation and symptom care remain essential.
References
- National Institute for Health and Care Excellence. Multiple sclerosis in adults: management (NG220). Updated 3 June 2026.
- Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24:850–865. doi:10.1016/S1474-4422(25)00270-4. PubMed.
- National Multiple Sclerosis Society. Understanding multiple sclerosis. Accessed 8 Nov 2026.
Medical disclaimer: Educational material only. New neurological deficits require assessment, sometimes emergently. Do not self-diagnose MS from MRI, begin high-dose steroids or change DMTs without specialist supervision.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.